You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
Caris will sequence DNA and RNA for certain cancer patients and potentially help Merus enroll cancer patients with NRG1 fusions in the Phase I/II eNRGy trial for zenocutuzumab.
The tool, which has been validated in two independent patient cohorts, uses artificial intelligence to predict patients likely to benefit from upfront FOLFOX.
The firm said the assays detect all classes of alterations including genomic signatures for microsatellite instability, tumor mutation burden, and loss of heterozygosity.
While the guidance may lead to more streamlined CDx indications in precision oncology, test developers will still need to generate evidence, perhaps with limited pharma support.
On the second day of the conference, updates came not just from the publicly traded industry giants but also privately held firms of interest, such as Caris and GenapSys.
The firms are combining Caris' somatic and Ambry's germline testing to provide clinicians with information on patients' cancers.
Negative results in recent trials have highlighted the challenges that newer genomic test makers must overcome in proving methods for personalized CUP treatment.
In response to CMS reopening its national coverage determination to address its germline testing policy, stakeholders point out areas of concern and confusion.
The editorial board of the Pittsburgh Post-Gazette says other lawmakers should take Florida's approach and provide additional protections against genetic discrimination.
The Hill reports 17 states and the District of Columbia are suing over a new policy that would strip international students of their visas if they only attend classes online.
Centers for Disease Control and Prevention employees call on the agency to label racism a public health crisis and examine its own policies, NPR reports.
In PNAS this week: genetic evidence for Inca resettlement, analysis of spermatogonial stem cell transcriptomes, and more.